NL-OMON44751
Completed
Not Applicable
A Maastricht Contrast-Induiced-Nehropathy Guideline study (AMACING): prevention guidelines - appropriate and cost effective? - AMACING study
Medisch Universitair Ziekenhuis Maastricht0 sites660 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- acute kidney injury (AKI)
- Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Enrollment
- 660
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients \*18 years of age, with moderate renal insufficiency (eGFR \*30ml/min/1\.73m2\), referred for prophylactic intravenous hydration before and after an elective contrast procedure.
Exclusion Criteria
- •emergency or intensive care patients, patients receiving or having received renal replacement therapy, patients with severe renal insufficiency (eGFR \<30ml/min/1\.73m2\), patients \<18 years of age, patients unable or unwilling to personally give informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
PRostate Evaluation for Clinically Important disease: Sampling using Image-guidance Or Not?Prostaatkanker detectieprostatecancerNL-OMON42747Radboud Universitair Medisch Centrum17
Completed
Not Applicable
A multicentre Prospective study in pAtients undergoing ventral herNia repair by open approach with intrA-peritoneal positioning using parietex* Composite vEntral pAtch.hernia / abdominal wall defect10041297NL-OMON40149Covidien8
Completed
Phase 4
A randomized, multicentre, double-blind, parallel, sham-controlled study of the gammaCore®, a non-invasive neurostimulator device for the acute relief of episodic and chronic cluster headache.cluster headaches10019231NL-OMON40599electroCore LLC35
Completed
Phase 4
A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 mcg o.d.) vs tiotropium (18 mcg o.d.) + salmeterol/fluticasone propionate FDC (50/500 mcg b.i.d.) in patients with moderate to severe COPDairflow limitationCOPD10024970NL-OMON43821TFS Trial Form Support BV28
Completed
Not Applicable
A Prospective, Multi-Center Study of the IlluminOss® Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus from Metastatic Bone Diseasebone healingupper arm fracture1001732210005944NL-OMON40648IlluminOss Medical In.4